Global Bispecific Antibody Market To Witness More Than 25% CAGR Growth Till 2029 Says Kuick Research
Delhi, March 17, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights:
-
Global Market Forecast Till 2029: > USD 36 Billion
-
Approved Bispecific Antibodies: 11
-
Yearly & Quarterly Sales Insight
-
Global & Regional Sales Insights
-
Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies
-
Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
-
Fast Track Approval, Orphan Designation & Priority Status Insights
-
Approved Bispecific Antibodies Pricing & Dosage Analysis
-
Top 30 Companies Developing Bispecific Antibodies Competitive Insight
-
800 Pages Clinical & Commercial Opportunity insight
Download Report:
https://www.kuickresearch.com/report-bispecific-antibody-market-bispecific-antibodies-market
Lomvastomig, a groundbreaking bispecific antibody developed by Genentech, a subsidiary of Roche, marks a transformative milestone in cancer immunotherapy. Its innovative mechanism of action involves targeting both programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), serving as a dual immune checkpoint inhibitor. This strategic approach aims to unleash the immune system's full potential by blocking multiple inhibitory pathways simultaneously, thereby bolstering anti-tumor immune responses. TIM-3, a key immune checkpoint receptor, frequently coexists with PD-1 on tumor-specific T cells, amplifying the effectiveness of the combined blockade and enhancing T-cell activation and proliferation beyond what is achievable with single receptor targeting.
When adminisered, Lomvastomig undertakes a dual-targeted approach, engaging with precision both TIM-3 and PD-1 receptors present on specific T cells. This intricate action disrupts the interaction between TIM-3 and its physiological ligands, while also hindering the activation of PD-1 by its ligands, namely programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). By effectively halting these inhibitory pathways, Lomvastomig unleashes the potential of antigen-specific T lymphocytes, spurring their activation and bolstering the process of cytotoxic T-cell-mediated tumor cell lysis. This multifaceted response holds the promise of curtailing tumor growth.
At present, Lomvastomig is at the forefront of clinical investigation, with phase 2 clinical trials underway to evaluate its efficacy and safety in the treatment of solid cancers. These trials focus on a diverse spectrum of malignancies, including esophageal squamous cell carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and metastatic melanoma. By targeting such a broad range of cancers, Lomvastomig holds promise as a versatile therapeutic option with the potential to benefit patients across various disease contexts.